Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Paulex Bio Highlights Peer-Reviewed Research Demonstrating Potential of PAL-119 to Regenerate and Restore the Function of Insulin-Producing Beta Cells in Diabetes

      Paulex Bio

      News provided by

      Paulex Bio Inc.

      Nov 18, 2026, 08:02 ET

      Share this article

      Share this article


      Mount Sinai-led study in Diabetologia shows PAL-119 stimulated human beta cell proliferation and enhanced markers of beta cell function

      Findings support development of PAL-119 as an investigational, disease modifying oral therapy for Type 1 and Type 2 diabetes

      SAN DIEGO, Nov. 18, 2026 /PRNewswire/ -- Paulex Bio Inc., a biopharmaceutical company focused on rebuilding the body's own insulin-producing capacity, today highlighted peer-reviewed research published in Diabetologia supporting PAL-119, its investigational oral therapy designed to regenerate and restore the function of insulin-producing beta cells in diabetes. The study, led by researchers at the Icahn School of Medicine at Mount Sinai, provides evidence that increasing beta cell numbers and enhancing the specialized characteristics needed for insulin production involve distinct biological mechanisms. PAL-119, identified in the publication as 2-2c, was one of only three of the seven DYRK1A inhibitors tested that both stimulated human beta cell proliferation and increased expression of markers associated with beta cell identity and function.

      The paper, "Harmine selectively enhances human beta cell identity markers and function via protein kinase A pathways" (DOI: 10.1007/s00125-026-06857-5), examined how different inhibitors of dual-specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A) affect human pancreatic islets. All seven inhibitors tested stimulated human beta cell proliferation, but only three, including PAL-119, also enhanced markers associated with the specialized characteristics that enable beta cells to produce insulin and respond to glucose. The authors attribute these additional effects of PAL-119 and the two other dual-acting compounds to a second target, independent of DYRK1A, that engages the protein kinase A (PKA) pathway. Using an affinity probe derived from PAL-119, the researchers identified the PKA regulatory subunit PRKAR1A as the lead candidate among proteins captured from human islets. The authors concluded that DYRK1A inhibitors are not interchangeable and that those that drive both beta cell proliferation (regeneration, proposed to be mediated by DYRK1A) and identity and function (restoration of function, proposed to be mediated by PKA) will likely be preferable for diabetes therapy.

      Of the three dual-acting compounds, only PAL-119 is being developed as a drug candidate; the other two, harmine and 5-iodotubercidin, are not suitable for development as drugs. Harmine is a naturally occurring plant product with well-documented off-target activity, including undesired effects on the central nervous system resulting from its ability to cross the blood-brain barrier and enter the brain. 5-Iodotubercidin is a genotoxic nucleoside analog used as a laboratory research tool.

      Loss and dysfunction of insulin-producing beta cells are central to both Type 1 and Type 2 diabetes. Current medicines can replace insulin and improve the body's response to it or stimulate insulin secretion. However, regenerating the patient's own beta cells remains an unmet therapeutic opportunity in both forms of the disorder. The findings support a development approach that seeks to increase beta cell numbers while enhancing their functional characteristics.

      "Our goal is to rebuild the body's own insulin-producing capacity by regenerating beta cells and enhancing the function that allows them to respond appropriately to glucose," said Miguel Sanjuan, Ph.D., Co-Founder, President and CEO of Paulex Bio. "This research strengthens the scientific rationale for pursuing both objectives with PAL-119. Building on Mount Sinai's foundational work in beta cell regeneration, PAL-119 was engineered to be highly target specific and to have a substantially reduced ability to cross the blood-brain barrier, the natural barrier that protects the brain. To our knowledge, PAL-119 is the only DYRK1A inhibitor in development shown both to regenerate beta cells and to enhance their function. We are advancing this approach toward clinical testing with the ambition of changing the course of diabetes and, ultimately, achieving a functional cure."

      PAL-119 is an oral small molecule designed to regenerate beta cells through DYRK1A inhibition and enhance beta cell function through PKA-associated signaling. These complementary, dual-action mechanisms offer the potential to both increase the number of functional beta cells and augment the body's ability to produce insulin in response to glucose. Paulex is advancing a Phase 1/2a program to evaluate PAL-119's safety, tolerability and pharmacokinetics and explore its effects on beta cell function, including measures of the body's own insulin production.

      About PAL-119
      PAL-119 is an investigational, dual-action oral small molecule designed to regenerate and restore the function of insulin-producing beta cells, with potential applications in Type 1 and Type 2 diabetes. Originating from research at the Icahn School of Medicine at Mount Sinai, PAL-119 acts to increase beta cell numbers through DYRK1A inhibition and enhance beta cell function through PKA-associated signaling. PAL-119 was engineered to overcome the liabilities of harmine, with improved target selectivity and substantially reduced brain exposure.

      About Paulex Bio
      Paulex Bio Inc. is a biopharmaceutical company focused on changing the course of diabetes by addressing the biological cause of the disease. Its lead candidate, PAL-119, is an investigational oral small molecule designed to regenerate and restore the function of insulin-producing beta cells, with potential applications in Type 1 and Type 2 diabetes. Paulex holds exclusive worldwide rights from the Icahn School of Medicine at Mount Sinai to PAL-119 and related compounds, including composition-of-matter patent families. For more information, visit www.paulexbio.com.

      Forward-Looking Statements
      This release contains forward-looking statements regarding Paulex Bio's research and development programs, including the potential benefits of its investigational therapies and the timing, progress and results of clinical trials. These statements reflect current expectations and are subject to risks and uncertainties that could cause actual results to differ materially, including risks related to clinical development, regulatory requirements, financing and the company's ability to advance its programs. Paulex Bio undertakes no obligation to update these statements, except as required by law.

      Contacts
      Tiberend Strategic Advisors, Inc.

      Investor Relations
      David Irish / Brooke Cooper
      231-632-0002 / 862-274-1134
      [email protected] / [email protected]

      Media Relations
      Eric Sagonowsky / Michelle Katsel
      734-904-8887/ 201-790-3390
      [email protected] / [email protected] 

      SOURCE Paulex Bio Inc.

      Modal title

      Also from this source

      Paulex Bio Receives NIH Fast-Track Grant to Advance Beta Cell Regeneration Therapy of PAL-119

      Paulex Bio Receives NIH Fast-Track Grant to Advance Beta Cell Regeneration Therapy of PAL-119

      Paulex Bio Inc., a biopharmaceutical company focused on rebuilding the body's own insulin-producing capacity, today announced that it received a...

      Paulex Bio Announces Registration of Phase 1/2a Trial of PAL-119, an Oral Small Molecule Designed to Regenerate and Restore the Function of Insulin-Producing Beta Cells

      Paulex Bio Announces Registration of Phase 1/2a Trial of PAL-119, an Oral Small Molecule Designed to Regenerate and Restore the Function of Insulin-Producing Beta Cells

      Paulex Bio Inc., a biopharmaceutical company focused on rebuilding the body's own insulin-producing capacity, today announced the registration of its ...

      More Releases From This Source

      Explore

      Health Care & Hospitals

      Health Care & Hospitals

      Biotechnology

      Biotechnology

      Pharmaceuticals

      Pharmaceuticals

      Clinical Trials & Medical Discoveries

      Clinical Trials & Medical Discoveries

      News Releases in Similar Topics

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.